Photo via South China Morning Post

ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom

Read the original at South China Morning Post ↗
Cite

Shen, X. (2026, September 18). ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom. South China Morning Post. https://www.scmp.com/business/china-business/article/3367926/bytedance-spin-anew-labs-raises-us290m-ai-drug-developers-enjoy-fundraising-boom?utm_source=rss_feed

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

South China Morning Post · collected 2026-09-18 · by Xinmei Shen

Quick Summary

Anew Labs, a Shanghai-based AI drug discovery company that was spun off from ByteDance, has raised $290 million at a valuation of $1.5 billion. Major investors include HSG (formerly Sequoia China), IDG Capital, and 5Y Capital, while ByteDance retains a 56% stake in the firm. Anew Labs specializes in AI models for predicting and designing biomolecular structures, including its own foundation model AnewFold and an open-source version of Google DeepMind’s AlphaFold 3 called Protenix.
Written by AI on 2026-09-18, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Anew Labs, a Shanghai-based artificial intelligence drug discovery firm formerly part of Chinese tech giant ByteDance, has raised US$290 million at an estimated valuation of US$1.5 billion. Investors in the round include major venture capital firms like HSG (formerly Sequoia China), IDG Capital, and 5Y Capital. The fundraising effort reflects a broader trend in China where AI-driven drug development start-ups are attracting significant investment as they compete with international players such as Anthropic and Isomorphic Labs. Anew Labs specializes in creating various AI models for predicting and designing biomolecular structures, including its own foundation model called AnewFold and an open-source version of AlphaFold 3 from Google DeepMind.

Written for “AI Drug Development Funding Boom” on 2026-11-02, grounded in this article and the 0 other(s) covering the same event.

Story

📰 AI Drug Development Funding Boom
Technology · 1 article(s) covering the same event.

Compared with similar articles

This article reads unscored and hedges 20% of its claims. Each row says how that neighbour differs.
Top Chinese AI models make 10% of OpenAI, Anthropic revenue despite high valuations: report Different event
South China Morning Post
Hedges 2 of 3 claims Outlet record 63/100
“The articles discuss different aspects of the AI industry's fundraising and revenue, not the same specific incident.”
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
5
sentences that state something as happening or true
Uncertain
20%
1 of 5 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
63/100
South China Morning Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Technology
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-18 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

South China Morning Post · 3568 article(s) · 7 correction(s) detected
Running correction rate · 7 correction(s)
2026-11-01
Former Apple Daily publisher joins mainland China tour for rehabilitated offenders
2026-10-16
Nobel Peace Prize: the message behind Navi Pillay’s win
2026-10-16
Indonesian governor’s Singapore trip adds fury to forest fire, haze crisis
2026-10-04
Flight to Okinawa diverts back to Hong Kong after suspected landing gear fault
2026-10-04
Tennessee prisons chief resigning after botched execution of Christa Pike
2026-09-29
Indonesian prison chief suspended over secret VIP compound for inmates
2026-09-28
Trump ‘arms offer’ to China jolts Washington into moves to contain the fallout

Who wrote this

Xinmei Shen
10 article(s) here · 0 carrying a prediction
🔮 Beijing-based cancer drug developer InnoCare Pharma said on Thursday that it had entered into a strategic research collaboration and licensing agreement with US pharmaceutical giant Eli Lilly that could be worth up to US$3.35 billion.
2026-09-26 · assertive framing · China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
🔮 Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
2026-09-23 · speculative framing · Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
Also by Xinmei Shen
Chinese drug sector’s stature grows at major cancer conference
2026-10-28 · South China Morning Post
Former HSBC executive launches wealth platform powered by team of AI agents
2026-10-12 · South China Morning Post
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
2026-10-07 · South China Morning Post
China’s biotech firms move up value chain as drug deals evolve beyond licensing: analysts
2026-09-26 · South China Morning Post
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 10 articles by Xinmei Shen →

Topics

Anew Labs ByteDance China Chinese Isomorphic Labs

Subjects

ByteDance ORG · 4× Anew Labs ORG · 3× Chinese NORP · 2× Isomorphic Labs ORG · 2× Anthropic ORG · 1× China GPE · 1× HSG ORG · 1× IDG Capital ORG · 1× Sequoia China ORG · 1× Shanghai GPE · 1×

Narrative

ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts China is seeing a fresh fundraising boom for AI drug developers, with start-ups including a ByteDance spin-off raising hundreds of millions of dollars this week as investors rush to back domestic challengers to Anthropic and Isomorphic Labs.
framing: assertive · carried by 1 article(s) · first seen 2026-09-18
2026-09-18 · South China Morning Post
ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom · assertive framing

Claims (5 extracted, 1 hedged)

ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts China is seeing a fresh fundraising boom for AI drug developers, with start-ups including a ByteDance spin-off raising hundreds of millions of dollars this week as investors rush to back domestic challengers to Anthropic and Isomorphic Labs. asserted
investors → raise → Anthropic
Anew Labs, a Shanghai-based AI drug discovery firm that was formerly a unit of Chinese tech giant ByteDance, has raised US$290 million at a valuation of US$1.5 billion, according to an informed source. uncertain
that → base → source
Investors included prominent venture capital firms such as HSG – formerly Sequoia China – IDG Capital and 5Y Capital, the source said, with ByteDance maintaining a 56 per cent stake. asserted
ByteDance → include → stake
Anew Labs, which did not immediately respond to a request for comment, operates a range of artificial intelligence models for biomolecular structure prediction and design. asserted
which → respond → prediction
They include AnewFold, its in-house foundation model, and Protenix, an open-source reproduction of AlphaFold 3, the most advanced biomolecular prediction AI model from Google DeepMind and its Isomorphic Labs spin-off. asserted
They → include → DeepMind
💬Give feedback
🕘History 🎫Support
Terms · Privacy · beta v2.0.0
Articles to 2 Nov 2026